|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
||||||||
|
|
New Patent Awarded, 2002 Innovative Growth Factor Applications for Non-Specific Inflammatory Conditions Biomed Comm,® Inc., a biotechnology company in the natural products industry, announces a new patent for its innovative homeopathic growth factor research. The patent, entitled Treatment methods using homeopathic preparations of growth factors, was awarded November 27, 2002 by the U.S. Patent and Trademark Office. Biomed Comm® has achieved much success in the area of homeopathic growth factors with its line of Cell Signal Enhancer® (CSE®) medicines sold over-the-counter (OTC). These medicines contain only recombinant, safe ingredients that are proven effective through double-blind, placebo controlled clinical studies. CSE® medicines facilitate cell-to-cell communication that is critical to all aspects of human health and well-being. “This new patent is further testimony to our commitment to sound scientific research in the area of homeopathic growth factors, including growth hormone,” says Biomed Comm,® Inc. founder and CEO, Barbara Brewitt, Ph.D. The new patent provides the company with the legal rights of reducing nonspecific inflammatory states in a person’s body using homeopathic growth factors alone or in combination. This new patent further provides the company with the legal rights to introduce OTC medicines that address health symptoms arising from the vital organs such as the liver, heart, lungs, skin, bones, and joints, all of which decline with age and are subject to nonspecific inflammation. Nonspecific inflammation also occurs in the sexual organs of uterus, prostate, testicles and ovaries. Aging is frequently associated with early indications of health problems such as poor blood flow, menopause, rheumatoid arthritis, asthma, irritable bowel syndrome, poor wound healing, heart disease, tooth and gum problems, early pre-cancerous conditions, and other chronic ailments and symptoms. Biomed Comm® successfully completed 10 double-blind, placebo controlled clinical studies and had 8 papers in U.S. peer-reviewed journals demonstrating that, in healthy and chronically ill people, its CSE® medicines reduce nonspecific inflammation quantified by objective blood measures. In both traditional homeopathic and conventional medical studies, treatment and placebo groups were distinctly different in the benefits gained by homeopathic growth factors. Dr. Brewitt and independent clinical investigators identified that oral delivery of homeopathic growth factors reduced nonspecific inflammation throughout the body, and that they are clinically proven effective and safe. Validating Biomed Comm,® Inc.’s efforts and credible science, the company has now received five patents from the U.S. Patent and Trademark Office with others patents pending. The company holds, among others, the only two U.S. patents for the composition of homeopathic recombinant human growth hormone and growth factor medicines. The protections provided by the U.S. Patent and Trademark Office legally grants a period of approximately 20 years exclusivity for innovative, patented medicines. Biomed Comm,® Inc. is the leader in evidence-based medicine for homeopathic growth factors from its original and replicated double-blind, placebo controlled clinical studies with healthy people as well as those with chronic symptoms. For more information, contact:
|
|
